Stocktoria
Ovid Therapeutics Inc. OVID
Ovid Therapeutics Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2025 | FY2024 | FY2024 | FY2024 | FY2024 | FY2023 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $223.6M | $566,000 | $223.4M | $223.2M | $223.0M | $392,000 | $222.8M | $222.6M | $222.6M |
| R&D expense | $25.6M | — | $36.8M | — | — | — | $28.6M | — | — | — |
| Operating income | -$42.4M | — | -$61.9M | — | — | — | -$59.3M | — | — | — |
| Income tax | $0 | — | $0 | — | — | — | $0 | — | — | — |
| Net income | -$17.4M | — | -$26.4M | — | — | — | -$52.3M | — | — | — |
| EPS (diluted) | — | — | — | — | — | — | $-0.74 | — | — | — |
| Operating cash flow | -$38.3M | — | -$56.0M | — | — | — | -$45.8M | — | — | — |
| Free cash flow | -$38.3M | — | -$56.0M | — | — | — | -$45.8M | — | — | — |
| Cash & equivalents | $13.2M | $21.1M | $26.3M | $15.0M | $29.7M | $30.8M | $27.0M | $57.4M | $71.6M | $63.1M |
| Total assets | $150.9M | $81.7M | $92.2M | $102.7M | $118.1M | $131.6M | $144.0M | $125.0M | $136.2M | $143.4M |
| Total liabilities | $20.3M | $22.4M | $23.9M | $26.4M | $29.2M | $53.3M | $56.2M | $23.7M | $25.5M | $22.4M |
| Shareholders' equity | $130.7M | $59.3M | $68.2M | $76.3M | $88.9M | $78.3M | $87.8M | $101.3M | $110.7M | $120.9M |
Growth · year-over-year · Revenue CAGR -31.6%
| Metric | FY2025 | FY2025 | FY2024 | FY2024 | FY2024 | FY2024 | FY2023 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -96.8% | +39405.3% | -99.7% | +0.1% | +0.1% | +56787.8% | -99.8% | +0.1% | +0.0% | +14712.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.